Big Law

Johnson & Johnson Sues Amgen for Patent Infringement of Drug

Johnson & Johnson’s  Janssen unit has sued Amgen Inc. over its plan to market a drug for ulcerative colitis and other conditions similar to J&J’s top-selling Stelara, saying it would infringe on two patents.

The lawsuit was made public Wednesday.

Stelara accounted for $9.1 billion of J&J’s $52 billion in global drug sales last year. Sales for the first nine months of this year were $7.3 billion, up 7.9% over the same period last year.

Read the source article at businessinsurance.com

Leave a Review or Comment

Back to top button